Close Menu

People in the News

Jul 02, 2020

Berkeley Lights: Greg Lucier

Greg Lucier has joined the board of directors of Berkeley Lights. He is the CEO of Corza Health and previously served as CEO of Nuvasive, where he remains chairman, and as chairman and CEO of Life Technologies. Prior to that, he held executive roles with General Electric. Lucier holds an MBA from Harvard Business School and a BS in industrial engineering from Pennsylvania State University.

Jun 29, 2020

Cergentis: Joris Schuurmans, Dirk Pollet, Maja Sanders

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

Jun 27, 2020

IsoPlexis: Peter Siesel

IsoPlexis has appointed Peter Siesel as chief commercial officer. Siesel joins IsoPlexis from Tecan, where he most recently served as senior vice president of sales and was responsible for commercialization in the Americas.

Jun 23, 2020

NeoGenomics: Cynthia Dieter

NeoGenomics announced the appointment of Cynthia Dieter as chief accounting officer and controller, effective June 22. Before coming to NeoGenomics, Dieter was the senior director of corporate accounting at Viasat. She has also served in multiple roles at DJO Global, including VP and assistant corporate controller, VP and vista controller, and director of financial reporting and planning. 

In addition, Dieter has been the manager of financial reporting at Captiva Software and audit manager for Ernst and Young. 

Jun 19, 2020

Guardant Health: Vijaya Gadde

Guardant Health has appointed Vijaya Gadde to serve on its Board of Directors. Gadde is Twitter's chief legal officer leading its legal, public policy, and trust and safety teams globally. Prior to joining Twitter in 2011, she was senior director, legal at Juniper Networks. Before that, she worked for nearly a decade at Wilson Sonsini Goodrich & Rosati. Gadde serves on the Board of Trustees of NYU Law School and the Board of Directors of Mercy Corps. She is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. She earned a JD from New York University School of Law and a BS in industrial and labor relations from Cornell University.

Jun 18, 2020

T2 Biosystems: Thierry Bernard, Ninfa Saunders, Robin Toft

T2 Biosystems has appointed Thierry Bernard, Ninfa Saunders, and Robin Toft to its board of directors. Bernard currently serves as CEO of Qiagen, Saunders is president and CEO of Navicent Health, and Toft is founder and CEO of Toft Group and previously served as senior vice president of commercial operations at Roche Molecular Diagnostics. T2 Biosystems also announced that Michael CimaAdrian Jones, and Stanley Lapidus will be leaving the firm's board of directors.

Jun 18, 2020

Waters: Christopher O'Connell

Christopher O'Connell will step down as president, CEO, and a member of the board of directors of Waters, the firm announced this week. Waters said that it has hired an executive search firm to identify a new CEO and that O'Connell will serve as an advisor until the end of this year to support the transition. O'Connell has served as president and CEO of Waters for the past five years, succeeding the firm's long-time leader Doug Berthiaume. According to terms of O'Connell's separation agreement, he will receive a cash severance in the amount of $4,252,500, payable over a two-year period following termination of employment and a bonus for calendar year 2020 based on the company's performance.

Jun 17, 2020

IonPath: Brad Nelson

IonPath has appointed Brad Nelson as senior vice president of marketing and corporate strategy. Nelson will lead marketing, product management, and application functions related to the company's multiplexed ion beam Imaging technology. Nelson most recently served as VP of marketing at Magnolia Medical Technologies. Prior to that he was head of marketing and director of corporate development at Labcyte (now part of Danaher). He also previously led marketing efforts at Velocity11, which was acquired by Agilent.

Jun 17, 2020

Phase Genomics: Kayla Young

Phase Genomics, a University of Washington spinout providing proximity-ligation next-generation sequencing solutions for metagenome assembly, has appointed Kayla Young as its chief operating officer. Young joined Phase Genomics in 2017 as director of operations. She also has previous experience at Life Science Washington, and received a PhD in molecular physiology and biophysics from Vanderbilt University in 2016.

Jun 15, 2020

Laboratory for Advanced Medicine: Samuel Tong

Laboratory for Advanced Medicine has appointed Samuel Tong as CEO for its operations in China. He joins the company from medical research organization NAMSA where he was vice president and general manager of the Asia-Pacific region. Prior to that, he was VP and GM for greater China at Qiagen. Tong was also business unit director of diagnostics systems for greater China at Becton Dickinson, and country manager of China at Abbott Vascular.

Jun 15, 2020

Foundation Medicine: Geoffrey Oxnard

Roche subsidiary Foundation Medicine announced Geoffrey Oxnard has been appointed vice president, global medical lead for the firm's liquid biopsy portfolio, effective immediately. In the role, he'll define research and a liquid biopsy-focused discovery roadmap while investigating novel applications of liquid biopsy approaches to improve cancer research and care.

Oxnard previously served as a thoracic oncologist and clinical investigator at the Dana-Farber Cancer Institute at Harvard Medical School, and he'll continue seeing patients part-time at the institute. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies and detecting occult cancer. 

Jun 12, 2020

Scipher Medicine: Jerry Conway

Scipher Medicine has named Jerry Conway as senior vice president of market access. He will focus on patient access to Scipher's precision diagnostic tools beginning with PrismRA, a molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis, and is slated to launch later this year. Conway most recently served as executive vice president at CDx Diagnostics.

Jun 12, 2020

AACC: Mark Golden

Mark Golden has been appointed the CEO of the American Association for Clinical Chemistry, effective Aug. 17. Prior to joining AACC, he was executive director and CEO of the National Society of Professional Engineers for seven years. AACC had previously said that its current CEO Janet Kreizman would retire from the organization.

Jun 11, 2020

Quidel: Jack Schuler

Jack Schuler has retired from Quidel's board, effective June 10, the firm said. Schuler, 79, has been on Quidel's board since February 2006. He was the former president and chief operating officer of Abbott Laboratories.

Jun 10, 2020

Pacific Biosciences: Michael Hunkapiller, Susan Barnes

Pacific Biosciences announced that CEO and President Michael Hunkapiller will retire by the end of the year. He plans to remain on the company's board. Hunkapiller served eight years as CEO and oversaw the launch of the Sequel and Sequel II instruments.

Susan Barnes, the firm's CFO and executive VP, will also retire in August after more than a decade with the company.

PacBio said it has already begun searching for their replacements.

Jun 05, 2020

Biomarker Strategies: Greg Bertenshaw

Biomarker Strategies has promoted Greg Bertenshaw to the position of chief operating and science officer. Bertenshaw was formerly vice president of R&D and director of R&D for the company, which he joined in 2011 as a senior scientist. Bertenshaw has also previously served as director of new technology for Correlogic Systems, and as a scientist and director of science for Clearant. He holds a PhD in biochemistry and molecular biology from Penn State University College of Medicine.

Jun 04, 2020

Viracor, Transplant Genomics: John Holman, Roz Mannon, Michael Abecassis, Fuad Shihab, Win Williams, Anil Chandraker, Allan Kirk, Jonathan Bromberg, Robert Fairchild, Matt Cooper

Transplant Genomics (TGI) and Viracor Eurofins announced that they have formed the Eurofins Transplant medical and scientific advisory board, which will be convened by Eurofins TGI's VP of Medical Affairs John Holman. The board will include Roz Mannon, University of Nebraska; Michael Abecassis, University of Arizona; Fuad Shihab, University of Utah; Win Williams, Massachusetts General Hospital; Anil Chandraker, Brigham and Women's Hospital; Allan Kirk, Duke University; Jonathan Bromberg, University of Maryland; Robert Fairchild, Cleveland Clinic; and Matt Cooper, Georgetown University.

The board consists of people with diverse expertise and experience in transplantation technology development and clinical studies, and will be tasked with providing independent advice on unmet clinical needs in transplantation to guide the evolution of TGI and Viracor's current and future products that expand the indications for its TruGraf and Trac product lines through clinical studies. The board will also provide advice on R&D or acquisition of additional disruptive technologies for the Eurofins transplant portfolio.

Jun 04, 2020

Oxford Biodynamics: Peter Pack

Oxford BioDynamics has appointed Peter Pack as independent non-executive chairman of the firm. He will be replacing Stephen Diggle, who will transition to the role of non-executive director. Prior to joining the firm's board in 2019 as non-executive director, Pack headed Crescendo Biologics from 2015 to 2019. Pack also served as cofounder and CEO of MTM laboratories prior to its acquisition by Roche Diagnostics. Before launching MTM laboratories, Pack began his career at MorphoSys. 

Jun 04, 2020

NeoGenomics: Rachel Stahler

NeoGenomics announced Rachel Stahler would join the company's board of directors, effective immediately. She will serve on the board's audit committee. Stahler was recently named the chief information officer for Merck's intended women's health and biosimilars spinoff Organon & Co. Previously, she was the CIO at pharmaceuticals firm Allergan, Syneos Health, and Optimer Pharmaceuticals. 

May 29, 2020

OraSure Technologies: Lelio Marmora

OraSure Technologies has appointed Lelio Marmora as a member of the company's board of directors, effective June 1. Marmora previously served as executive director of Unitaid and also held senior positions at the Global Fund to Fight AIDS, TB and, Malaria.

May 29, 2020

Castle Biosciences: Federico Monzon

In a filing with the US Securities and Exchange Commission, Castle Biosciences said that Chief Medical Officer Federico Monzon notified the company on May 21 that he plans to resign, effective May 31. In November 2019, the firm had disclosed Monzon's intention to resign on or about April 1, 2020, but the move was subsequently delayed. 

May 28, 2020

Pacific Biosciences: Eric Schaefer

On May 26, Pacific Biosciences appointed Eric Schaefer to the role of vice president and chief accounting officer, effective immediately. He succeeds Susan Barnes as the principal accounting officer.

Schaefer previously served as PacBio's senior director, corporate controller. He joined the firm in 2012 from PricewaterhouseCoopers and is a certified public accountant.

May 28, 2020

Myriad Genetics: John Henderson, Daniel Spiegelman

Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point Louise Phanstiel was elected to serve as chair. The company has also elected to its board of directors Daniel Spiegelman, who was most recently executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.

May 27, 2020

Flagship Biosciences: Aymii Couzelis

Flagship Biosciences has promoted Aymii Couzelis to CIO. As such, she will oversee scaling of technology across software development, the customer help desk, network engineering, project management, quality assurance, laboratory operations, and data security, the company said. Couzelis has been with Flagship Biosciences for about a year, previously as technology manager. She formerly was CIO of corporate wellness firm MediFit Corporate Services.

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry as its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.